

TRANSMITTAL LETTER

Inventor: Matthias Schuster  
Serial No: 10/562,023  
Filed: June 17, 2004

Examiner: Unknown  
Group Art Unit: Unknown  
Confirmation No: 5401

For: METHOD FOR INVESTIGATING CYTOSINE METHYLATION IN DNA SEQUENCES  
BY MEANS OF TRIPLEX-FORMING OLIGOMERS

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Transmitted herewith for the above-identified patent application are the following:

- A Notification to Comply with Requirements dated January 29, 2007
- A Sequence Listing Transmittal and Statement
- A Sequence Listing on paper
- A Sequence Listing in computer readable form
- A return postcard

The item(s) checked below are appropriate:

1. \_\_\_ Applicant(s) hereby petition(s) for a ( ) month extension of time to respond to an
1755. 2. ☒ Please charge any fees or costs not accounted for to Deposit Account No. 11-
3. ☒ Applicant is a small entity.

Date: March 29, 2007

  
Edward M. Kriegsman  
Reg. No. 33,529

KRIEGSMAN & KRIEGSMAN  
30 Turnpike Road, Suite 9  
Southborough, MA 01772  
(508) 481-3500

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 29, 2007.

  
Edward M. Kriegsman



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/562,023	Matthias Schuster	82493

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/EP04/06534

I.A. FILING DATE	PRIORITY DATE
06/17/2004	06/20/2003

23685

KRIEGSMAN & KRIEGSMAN  
 30 TURNPIKE ROAD, SUITE 9  
 SOUTHBOROUGH, MA 01772

CONFIRMATION NO. 5401

371 FORMALITIES LETTER



\*OC000000022199566\*

Date Mailed: 01/29/2007

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

CHRISTINE S WASHINGTON

Telephone: (703) 308-9140 EXT 228

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/562,023	PCT/EP04/06534	82493

FORM PCT/DO/EO/922 (371 Formalities Notice)